Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.

EMA's approval was based on a single pivotal trial presenting critical limitations, rendering the results from the trial potentially inconclusive. The broad dissemination of TIVO-1 results in the scientific literature may have been affected by spin or results were presented in an inadequate critical manner.